Project Grant 1DMC00187A00000

Federal Grant Award Summary Emory University received a $391,211 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective June 1, 2026 through May 31, 2029. The project, titled "Alloimmune Responses to Hemophilia Therapeutics," will conduct research to advance understanding of inhibitor development in hemophilia patients receiving factor replacement therapies. Specifically, the research...

Federal Project Grant Award Summary Emprime Therapeutics Inc. received a $314,363 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded on September 15, 2025, with completion targeted for August 31, 2026. The award funds development of a novel dual adeno-associated virus (AAV) vector technology called STITCHR (Specific Trans-Ligation of Cognate RNA) designed to deliver and express full-length Factor VIII...

Federal Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded New Health Sciences, Inc. (doing business as Hemanext Inc.) a Project Grant of $1,017,232 under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct a rigorous clinical efficacy trial of hypoxic red blood cell (HRBC) transfusions for sickle cell anemia patients. The award, issued on September 5, 2025, with completion targeted for August 31, 2028, will fund the first comparative...

The District of Columbia Department of Health Care Finance (DHCF) received a Cooperative Agreement award of $4,153,512 (obligated funds against a total project budget of $7,072,261) from the Centers for Medicare and Medicaid Services (CMS) under the Cell and Gene Therapy (CGT) Access Model (CFDA 93.885), effective August 1, 2025 through December 31, 2035. This award supports DHCF's implementation of the CGT Access Model, a voluntary federal initiative designed to expand Medicaid beneficiaries'...

Grant Award Summary Emory University received a $941,106 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective July 7, 2025, through June 30, 2027. The award funds research investigating the genetic regulation of Factor VIII (FVIII) inhibitor development in hemophilia A patients. The project will utilize Diversity Outbred mice—an outbred population generated through...

Federal Project Grant Award Summary Vitalant Research Institute received a $262,500 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective September 15, 2025, with completion targeted for August 31, 2027. The award funds research aimed at defining the drivers of mitochondrial DNA (mtDNA) levels in blood components and investigating their impact on transfusion-related acute lung injury (TRALI). The...

Federal Grant Award Summary Award Details: The National Heart, Lung, and Blood Institute (NHLBI) awarded Emory University a Project Grant totaling $646,383 under the Cardiovascular Diseases Research program (CFDA 93.837). The award was obligated on September 15, 2025, with an ultimate completion date of June 30, 2030. Research Scope and Deliverables: This project investigates red blood cell (RBC) transfusion survival and effectiveness in recipients with sickle cell disease (SCD), a clinical...

This $2,696,128 federal Project Grant award, funded under the Department of Defense's Military Medical Research and Development program (CFDA 12.420), supports preclinical development of a gene replacement therapy using novel adeno-associated virus (AAV) vectors to treat familial cerebral cavernous malformations (CCM). The prime awardee is Duke University, which is collaborating with the University of Chicago as a sub-awardee. Duke's work focuses on developing the gene therapy treatment, while...

Federal Grant Award Summary Cincinnati Children's Hospital Medical Center received a $441,375 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded August 15, 2025, with completion targeted for July 31, 2027. The award funds research to develop and optimize a dual adeno-associated virus (AAV) gene delivery system employing intein technology to deliver full-length, functional cystic fibrosis transmembrane...

Federal Project Grant Award Summary Albert Einstein College of Medicine received a $327,240 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded July 9, 2025, with completion scheduled for March 31, 2028. This grant funds research to elucidate the interplay between DDX41 (DEAD-box helicase 41) and CUX1 (Cut-like homeobox 1) mutations in hematopoiesis using zebrafish (Danio rerio) and human induced...